Lymphoma, Leukemia & Myeloma Congress

Where hematology-oncology professionals come together. Follow for updates, education, and community.

October 13-16, 2026 | New York City

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Behind every diagnosis is a person, a family, and a life that continues through and beyond cancer care.

Recognizing survivors today, and the caregivers and clinical teams who support them.

#NationalCancerSurvivorsDay #LLMCongress

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

The response data for Venetoclax in high-risk MDS is compelling but the questions around durability, toxicity, and patient selection are not settled.

Drs. @yasminabaza1 and @Anand_88_Patel debate it at #LLMGreatDebates

Learn more about the debate: https://t.co/2cAraRixB7 

#MDS #Leukemia #Hematology @UChicagoMed @NorthwesternMed

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Survivorship does not look the same for everyone.

During National Cancer Survivor Month, we recognize those living with, through, and beyond cancer, along with the families, caregivers, and clinical teams beside them.

#NationalCancerSurvivorMonth #cancercare

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

BV and PD-1 inhibitors are producing deep responses in relapsed Hodgkin Lymphoma. So, does transplant still have a role?

@lisaroth_md and Dr. Elif Yilmaz debate this at #LLMGreatDebates.

https://t.co/TOMIskErO9 

#Lymphoma #Hematology @WeillCornell @UTSWMedCenter @utswcancer

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Dr. Elias Jabbour of @UTMDAnderson has seen major progress in hematology over the course of his career. At LL&M Great Debates, he joins faculty from across the field to discuss where the evidence is moving, where controversy remains, and how clinicians are thinking through the next steps in care.

June 27–28 | New York City
July 25–26 | Dallas

https://t.co/xiXYsYeIu7

#LLMGreatDebates #Leukemia #Hematology #Oncology

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Blood cancers impact thousands of patients and families each year—driving ongoing advancements in diagnosis, treatment, and long-term care.

At LL&M Congress, we remain focused on delivering the latest clinical insights to support hematology/oncology professionals on the front lines.

Explore upcoming event details: https://t.co/kVrJoOrJbW

#BloodCancerAwareness #Hematology #Oncology #LLMCongress

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

BCMA-directed therapy at first relapse: deploy it for everyone, or save it for the right patient?

@DrKrinaPatel and @myelomadrkapoor present opposing sides and they'll both make a compelling case.

#LLMGreatDebates | NYC & Dallas 2026 → https://t.co/lwxU4FX8EW

#Myeloma #Hematology @UTMDAnderson @MayoClinic

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

MRD is becoming an increasingly important part of treatment decision-making across hematologic malignancies, but questions still remain around when and how it should guide care.

At the Lymphoma, Leukemia & Myeloma Congress, leading clinicians will explore the evolving role of MRD in risk stratification, therapy selection, monitoring strategies, and clinical decision-making across ALL, myeloma, and CLL.

Featured sessions include:
▪ Beyond Remission: Harnessing MRD to Personalize Treatment in ALL
▪ MRD Debate: Decision-Making Tool or Premature Metric?
▪ Integrating BTK and BCL-2 Inhibition Across the CLL Treatment Continuum

Join us October 13–16 in New York City to hear how experts are approaching MRD today — and where the field may be headed next.

Register now: https://t.co/5XO5Kn6Wyx

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

How would you approach these leukemia cases in practice?

Join Drs. @Anand_88_Patel, @aditishasMD, @yasminabaza1, @Daver_Leukemia, and Elias Jabbour for a case-based discussion on treatment strategies that matter in real-world care.

If you want to see how five of the field's most respected leukemia clinicians think: https://t.co/8uIZrsk823 

#LLMGreatDebates #Leukemia #Hematology @UTMDAnderson @MontefioreNYC @NorthwesternMed @UChicagoMed

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

We’re now accepting abstract submissions for the Lymphoma, Leukemia & Myeloma Congress, taking place October 13–16 in New York City. New this year, physical posters will be presented in our exhibit hall — creating even more opportunities to share research, exchange ideas, and connect face-to-face with peers and faculty.

Submit your original research, clinical data, and case-based insights for the opportunity to:
✔ Present onsite through physical poster sessions
✔ Share your work with a multidisciplinary hematology oncology audience
✔ Be published in the American Journal of Hematology

Submit by July 15, 2026
Abstract submitters receive $100 off the lowest available registration rate.

Submit abstracts here: https://t.co/foA4IqFeNS

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Smoldering myeloma: intervene early, or keep watching?

Dara has the data. But early treatment in an asymptomatic patient is a different kind of decision.

@HadidiSamer and @myelomaMD will debate this at #LLMGreatDebates

NYC & Dallas 2026 → https://t.co/GKctx6W6Hl

#Myeloma #Hematology

@MayoClinic @UTSWMedCenter

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Is "Watch and Wait" still the right call in asymptomatic follicular lymphoma?

@DrCarlaCasulo will argue yes. @johnpleonardmd will contend the data is shifting.

One session. Two positions. You decide.

[https://t.co/WzWHS4Fs6G 

#LLMGreatDebates #Lymphoma #Hematology @nyulangone @Perlmutter_CC @WilmotCancer @URMed_DeptMed

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Behind every patient outcome is a coordinated effort across the care team.

From inpatient care to long-term management, multidisciplinary collaboration continues to shape progress in hematologic malignancies.

Learn more about upcoming LL&M events: https://t.co/i48XoggOlY

#HematologyOncology #PatientCare #LLMCongress

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Fixed duration or continuous therapy in frontline CLL?

The answer isn't settled, and Drs. Farrukh Awan and @pilladaywithdra will make sure you know why.

Depth of response. Resistance patterns. Patient priorities. All of it, on the table.

https://t.co/bdn6jLiMS9 

#CLL #Hematology #LLMGreatDebates @WeillCornell @UTSWMedCenter

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

During Nurses Week, we acknowledge the ongoing impact of oncology and hematology nurses in patient care, education, and treatment management.

Your role is central to advancing care delivery and supporting patients at every stage—reinforcing the importance of staying current with evolving clinical insights.

Explore upcoming opportunities to stay informed: https://t.co/b3lt1tvWJD

#NursesWeek #OncologyNurses #HealthcareProfessionals

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

CAR T. Bispecifics. Transplant.

One of these might not belong in the frontline anymore… or maybe it still does.

Drs. @szusmani and @JKaufmanMD take opposing sides at #LLMGreatDebates.

Join the Debates: https://t.co/6qteAuFQ39

#Myeloma #Hematology @MSKCancerCenter @WinshipAtEmory

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

📣 Meet the Co-Chairs for LL&M Great Debates

@jmikhaelmd leads myeloma, @jaltmanmd leads leukemia, and @johnpleonardmd leads lymphoma. Together with Emeritus Chair Morton Coleman, MD, they’re guiding this year’s program.

The focus isn’t just on new data. It’s on how that data is actually being used in practice, where approaches differ, and how those decisions play out for patients.

Explore the agenda:
https://t.co/4u3dkDp1Pf

📆 June 27–28, 2026 | New York City
📆 July 25–26, 2026 | Dallas

#LLMGreatDebates #Hematology #Oncology #Leukemia #Lymphoma #Myeloma

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Triplet vs quadruplet therapy in multiple myeloma. How are you approaching induction today?

Quadruplet regimens are driving deeper responses and improved outcomes in clinical trials, building on established triplet backbones. But in practice, the decision is more nuanced.

From tolerability and patient selection to risk stratification and long-term treatment goals, applying these regimens requires careful clinical judgment.

“We’re seeing strong data supporting deeper responses with quadruplet regimens. At the same time, applying these approaches in practice requires thoughtful consideration of the individual patient.” — Ruben Niesvizky, MD

At LL&M Congress, leading experts will examine how evolving induction strategies are shaping real-world decision-making in myeloma care.

Join us this October and gain practical insights to guide your treatment approach.

Register now with early bird pricing: https://t.co/MLs9Kqt9eE

#Hematology #Oncology #MultipleMyeloma #MedicalEducation

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

AML question that doesn’t have a clean: Start targeted therapy early or save it for later?

@Daver_Leukemia vs @aditishasMD take it head-on.

See More: https://t.co/gbcjHYMxkg

#AML #Hematology #Oncology #LLMGreatDebates

[Lymphoma, Leukemia & Myeloma Congress @llmcongress]

Treatment duration in CLL is evolving, and with it, how clinicians are approaching long-term disease management.

From fixed-duration regimens to the growing role of MRD, new strategies are creating more individualized treatment pathways. The opportunity for treatment-free intervals in some patients, alongside continuous therapy for others, is shifting how care decisions are made.

At LL&M Congress, leading experts will break down how emerging data is shaping these approaches in real-world practice.

“CLL treatment continues to evolve, with new strategies allowing us to better tailor therapy to the individual patient by applying data from clinical trials in more personalized ways.” — Richard Furman, MD

Join us this October to gain practical insights you can apply to treatment decisions in your clinic.

Register now with early bird pricing: https://t.co/H0Dh4o76OQ

#Hematology #Oncology #CLL #MedicalEducation